Login to Your Account



TTNP Plummets 42%

Committee to Scrutinize Titan's Implantable Buprenorphine

By Catherine Shaffer
Staff Writer

Tuesday, March 19, 2013
Briefing documents released ahead of a scheduled meeting March 21 of the Psychopharmacologic Drugs Advisory Committee sent shares of Titan Pharmaceuticals Inc. plummeting 41.7 percent Tuesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription